世界の前立腺疾患治療市場は、2021年の318億ドルから、2026年までに489億ドルに達し、予測期間中のCAGRは9.0％と予想されます。前立腺（前立腺）は男性の生殖器系の器官です。前立腺疾患の最も一般的な3つの形態は、炎症（前立腺炎）、非癌性の前立腺肥大（良性前立腺肥大症またはBPH）、および前立腺癌です。良性前立腺肥大症（BPH）は、男性が罹患する疾患として定義されています。それは、前立腺の非癌性の肥大を伴います。BPHが40歳以前に症状を示すことは稀ですが、BPHにかかるリスクは年齢とともに増加します。この疾患は、51歳から60歳までの男性のほぼ50％、80歳以上の男性の最大90％に影響を及ぼします。BPHの患者には、投薬や手術などの治療法が使用されてきました。
前立腺疾患治療市場は業績が低迷し、その傾向は2020年12月下旬まで続きました。規制やガイドラインの不利な変更が、この業界の成長を妨げています。世界中の主要な規制当局（CDC、WHO、MHRA、TGA、EMAなど）は、癌患者は健康な成人よりもCOVID-19感染のリスクが高いことを確認しています。したがって、スクリーニング、診断検査、および外科手術は、病院や癌治療センターで厳しく制限または延期されます。これにより、前立腺疾患治療市場に混乱が生じることが予想されます。その結果、待機的手術とスクリーニングに遅れが生じるでしょう。しかし、オンコロジーの予約数の増加、未処理分や新規症例の解消、ヘルスケアサービスの完全再開などによる前立腺がん治療などにより、2020年下半期から徐々に市場は拡大してきました。
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 17)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 LIMITATIONS OF THE CURRENT EDITION OF THE REPORT
2 RESEARCH METHODOLOGY (Page No. - 21)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
2.2.2 GROWTH FORECAST
2.2.3 TOP-DOWN APPROACH
FIGURE 4 PROSTATE HEALTH MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY
3 MARKET DYNAMICS (Page No. - 28)
3.1 MARKET DYNAMICS
FIGURE 6 PROSTATE HEALTH MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
3.1.1 DRIVERS
3.1.1.1 Increasing prevalence of benign prostatic hyperplasia
FIGURE 7 SHARE OF THE MALE POPULATION AGED 65 AND ABOVE, GLOBAL (2015-2019)
3.1.1.2 Increasing obesity
3.1.1.3 Investments, funds, and grants for research in BPH treatment
3.1.1.4 Rising prevalence of prostate cancer
3.1.1.5 Increasing demand for hormone therapy drugs
3.1.1.6 Emerging therapies for prostate cancer
TABLE 1 SELECT THERAPIES IN THE PHASE III PIPELINE FOR PROSTATE CANCER
3.1.2 RESTRAINTS
3.1.2.1 Side-effects associated with BPH medications
TABLE 2 SIDE-EFFECTS OF BPH DRUGS
3.1.3 OPPORTUNITIES
3.1.3.1 Emerging markets
3.1.3.2 Promising product pipeline
TABLE 3 PIPELINE DRUGS
3.1.4 CHALLENGES
3.1.4.1 Low awareness regarding prostate health among men
3.1.4.2 Product recalls in the prostate health market
TABLE 4 PRODUCT RECALLS IN THE PROSTATE HEALTH MARKET
4 PROSTATE HEALTH MARKET, BY DISEASE TYPE (Page No. - 35)
4.1 INTRODUCTION
TABLE 5 PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
4.2 PROSTATE CANCER
TABLE 6 PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 7 PROSTATE CANCER MARKET, BY REGION, 2018-2026 (USD MILLION)
4.2.1 AR-DIRECTED THERAPIES
4.2.1.1 AR-directed therapies are expected to remain the dominant drug class for the treatment of prostate cancer
TABLE 8 AR-DIRECTED THERAPIES MARKET, BY REGION, 2018-2026 (USD MILLION)
4.2.2 HORMONE ADT
4.2.2.1 ADT is the most common form of hormonal treatment
TABLE 9 HORMONAL ADT MARKET, BY REGION, 2018-2026 (USD MILLION)
4.2.3 CYTOTOXIC AGENTS
4.2.3.1 Newer cytotoxic agents are being studied in prostate cancer with the goal of achieving FDA approvals
TABLE 10 CYTOTOXIC AGENTS MARKET, BY REGION, 2018-2026 (USD MILLION)
4.2.4 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
4.2.4.1 PARP inhibitors are expected to be the leading drug class for the treatment of prostate cancer
TABLE 11 PARP INHIBITORS MARKET, BY REGION, 2018-2026 (USD MILLION)
4.2.5 OTHER THERAPIES
TABLE 12 OTHER THERAPIES MARKET, BY REGION, 2018-2026 (USD MILLION)
4.3 BENIGN PROSTATIC HYPERPLASIA
TABLE 13 BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 14 BPH DRUG TREATMENT MARKET, BY REGION, 2018-2026 (USD MILLION)
4.3.1 ALPHA BLOCKERS
TABLE 15 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 16 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION, 2018-2026 (USD MILLION)
4.3.1.1 Tamsulosin
4.3.1.1.1 Tamsulosin has been prescribed for BPH since 2000
TABLE 17 TAMSULOSIN MARKET, BY REGION, 2018-2026 (USD MILLION)
4.3.1.2 Silodosin
4.3.1.2.1 Benefits of silodosin and the launch of generics to support market growth
TABLE 18 SILODOSIN MARKET, BY REGION, 2018-2026 (USD MILLION)
4.3.1.3 Alfuzosin
4.3.1.3.1 Side-effects and fewer generic launches have hindered market growth to some extent
TABLE 19 ALFUZOSIN MARKET, BY REGION, 2018-2026 (USD MILLION)
4.3.1.4 Doxazosin
4.3.1.4.1 Doxazosin was introduced in 2005 and has seen many generic launches since
TABLE 20 DOXAZOSIN MARKET, BY REGION, 2018-2026 (USD MILLION)
4.3.1.5 Other alpha blockers
TABLE 21 OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018-2026 (USD MILLION)
4.3.2 5-ALPHA REDUCTASE INHIBITORS
TABLE 22 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 23 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION, 2018-2026 (USD MILLION)
4.3.2.1 Dutasteride
4.3.2.1.1 Availability of generics post-patent expiry to support market growth
TABLE 24 DUTASTERIDE MARKET, BY REGION, 2018-2026 (USD MILLION)
4.3.2.2 Finasteride
4.3.2.2.1 Finasteride is less effective than alpha blockers in improving LUTS
TABLE 25 FINASTERIDE MARKET, BY REGION, 2018-2026 (USD MILLION)
4.3.3 OTHER DRUG CLASSES
TABLE 26 OTHER BPH DRUG CLASSES MARKET, BY REGION, 2018-2026 (USD MILLION)
4.4 PROSTATITIS
TABLE 27 PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 28 PROSTATITIS MARKET, BY REGION, 2018-2026 (USD MILLION)
4.4.1 PRESCRIPTION PRODUCTS
4.4.1.1 Prescription drugs account for the larger share of the products used for the treatment of prostatitis
TABLE 29 PRESCRIPTION PRODUCTS MARKET, BY REGION, 2018-2026 (USD MILLION)
4.4.2 OVER-THE-COUNTER PRODUCTS
4.4.2.1 Sales of OTC products have risen over the past few years
TABLE 30 OVER-THE-COUNTER PRODUCTS MARKET, BY REGION, 2018-2026 (USD MILLION)
5 PROSTATE HEALTH MARKET, BY REGION (Page No. - 51)
5.1 INTRODUCTION
TABLE 31 PROSTATE HEALTH MARKET, BY REGION, 2018-2026 (USD MILLION)
5.2 NORTH AMERICA
TABLE 32 NORTH AMERICA: PROSTATE HEALTH MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
TABLE 33 NORTH AMERICA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 34 NORTH AMERICA: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 35 NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 36 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 37 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 38 NORTH AMERICA: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.2.1 US
5.2.1.1 The US holds the largest share of the North American market
TABLE 39 US: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 40 US: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 41 US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 42 US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 43 US: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 44 US: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.2.2 CANADA
5.2.2.1 Rising geriatric population and product approvals to support market growth
TABLE 45 CANADA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 46 CANADA: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 47 CANADA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 48 CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 49 CANADA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 50 CANADA: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.3 EUROPE
TABLE 51 EUROPE: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 52 EUROPE: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 53 EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 54 EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 55 EUROPE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 56 EUROPE: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 57 EUROPE: PROSTATE HEALTH MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
5.3.1 GERMANY
5.3.1.1 Increasing healthcare expenditure to support German market growth
TABLE 58 GERMANY: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 59 GERMANY: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 60 GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 61 GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 62 GERMANY: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 63 GERMANY: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.3.2.1 Availability of innovative treatment options to drive the market in the UK
TABLE 64 UK: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 65 UK: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 66 UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 67 UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 68 UK: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 69 UK: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.3.3 FRANCE
5.3.3.1 Rising geriatric population to accelerate the growth of the market
TABLE 70 FRANCE: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 71 FRANCE: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 72 FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 73 FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 74 FRANCE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 75 FRANCE: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.3.4 REST OF EUROPE
TABLE 76 ROE: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 77 ROE: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 78 ROE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 79 ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 80 ROE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 81 ROE: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.4 ASIA PACIFIC
TABLE 82 ASIA PACIFIC: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 83 ASIA PACIFIC: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 84 ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 85 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 86 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 87 ASIA PACIFIC: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 88 ASIA PACIFIC: PROSTATE HEALTH MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
5.4.1 JAPAN
5.4.1.1 Japan holds the largest share of the APAC market
TABLE 89 JAPAN: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 90 JAPAN: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 91 JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 92 JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 93 JAPAN: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 94 JAPAN: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.4.2 CHINA
5.4.2.1 Increasing obese population to support market growth
TABLE 95 CHINA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 96 CHINA: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 97 CHINA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 98 CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 99 CHINA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 100 CHINA: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.4.3 INDIA
5.4.3.1 Rising prevalence of obesity to accelerate market growth in India
TABLE 101 INDIA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 102 INDIA: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 103 INDIA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 104 INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 105 INDIA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 106 INDIA: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.4.4 REST OF ASIA PACIFIC
TABLE 107 ROAPAC: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 108 ROAPAC: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 109 ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 110 ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 111 ROAPAC: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 112 ROAPAC: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.5 LATIN AMERICA
5.5.1 LATAM MARKETS DRIVEN BY GROWING PATIENT BASE
TABLE 113 LATAM: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 114 LATAM: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 115 LATAM: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 116 LATAM: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 117 LATAM: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 118 LATAM: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
5.6 MIDDLE EAST AND AFRICA
5.6.1 MEA COUNTRIES HOLD SMALLEST SHARE OF GLOBAL MARKET
TABLE 119 MEA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 120 MEA: PROSTATE CANCER MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 121 MEA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018-2026 (USD MILLION)
TABLE 122 MEA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 123 MEA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018-2026 (USD MILLION)
TABLE 124 MEA: PROSTATITIS MARKET, BY PRODUCT, 2018-2026 (USD MILLION)
6 COMPETITIVE LANDSCAPE (Page No. - 87)
6.1 OVERVIEW
6.2 REVENUE ANALYSIS OF BPH TREATMENT MARKET
6.2.1 BPH MARKET REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS
FIGURE 8 TOP 5 PLAYERS HAVE DOMINATED THE MARKET IN THE LAST 3 YEARS
6.3 REVENUE ANALYSIS OF PROSTATE CANCER THERAPEUTICS MARKET
6.3.1 PROSTATE CANCER THERAPEUTICS REVENUE ANALYSIS OF TOP 5 MARKET PLAYERS
FIGURE 9 TOP 4 PLAYERS HAVE DOMINATED THE MARKET IN THE LAST 3 YEARS
6.4 MARKET SHARE ANALYSIS, 2020
6.4.1 PROSTATE HEALTH MARKET SHARE ANALYSIS, 2020
FIGURE 10 PROSTATE HEALTH MARKET SHARE ANALYSIS, 2019
6.5 COMPANY EVALUATION MATRIX
6.5.1 STARS
6.5.2 EMERGING LEADERS
6.5.3 PERVASIVE COMPANIES
6.5.4 PARTICIPANTS
FIGURE 11 PROSTATE HEALTH MARKET: COMPANY EVALUATION MATRIX, 2020
7 COMPANY PROFILES (Page No. - 92)
7.1 GLAXOSMITHKLINE
7.2 ASTELLAS PHARMA
7.3 MERCK
7.4 ELI LILLY AND COMPANY
7.5 ABBOTT LABORATORIES
7.6 JOHNSON & JOHNSON SERVICES, INC.
7.7 ABBVIE
7.8 ASTRAZENECA
7.9 SANOFI
7.1 PFIZER, INC.
8 APPENDIX (Page No. - 97)
8.1 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
8.2 AVAILABLE CUSTOMIZATIONS
8.3 AUTHOR DETAILS
